中国经济网北京3月12日讯迪哲医药(688192.SH)今日收报49.19元，跌幅3.00%，总市值228.55亿元。该 股目前处于破发状态。 迪哲医药于2021年12月10日在上交所科创板上市，发行股票4000.01万股，发行价格为52.58元/股。 迪哲医药首次公开发行股票的保荐人(主承销商)为中信证券股份有限公司，保荐代表人为丁元、彭浏 用，联席主承销商为华泰联合证券有限责任公司。该公司发行费用总额为1.17亿元，其中，承销费及保 荐费9564.42万元。 根据立信会计师事务所(特殊普通合伙)2025年4月10日出具的《验资报告》(信会师报字[2025]第ZA10726 号)，本次发行最终获配发行对象共计14名，发行价格为43.00元/股，本次发行数量为41,764,808股，募 集资金总额为1,795,886,744.00元，扣除不含税发行费用人民币22,440,613.47元，募集资金净额为人民币 1,773,446,130.53元。迪哲医药本次向特定对象发行A股股票的保荐机构为华泰联合证券，保荐代表人为 许超、丁明明。 迪哲医药2次募资合计募集资金38.99亿元。 迪哲医药首次公开发行股票募集资金 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2026-011 迪哲（江苏）医药股份有限公司 关于提前归还临时补充流动资金的闲置募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2026 年 3 月 6 日，公司已提前归还临时补充流动资金的闲置募 集资金人民币 10,336.33 万元。 一、募集资金临时补充流动资金情况 迪哲（江苏）医药股份有限公司（以下简称"公司"）于2025年4月29日召开 了第二届董事会第十三次会议、第二届监事会第十一次会议，审议通过了《关于 使用部分闲置募集资金临时补充流动资金的议案》，同意公司根据募集资金投资 项目的资金使用计划及项目的建设进度，在确保不影响募集资金投资项目建设进 度的前提下，使用总额不超过60,000万元（含本数）的部分闲置募集资金临时补 充流动资金，并仅用于与主营业务相关的生产经营使用，使用期限自董事会审议 通过之日起不超过12个月，到期归还至募集资金专用账户。具体内容详见公司于 2025年4月30日在上海证券交易所（www.sse.c ...

Core Viewpoint - Dige Pharmaceutical reported a significant increase in revenue for the year 2025, achieving a total operating income of 801.14 million yuan, which represents a year-on-year growth of 122.60% [2] Group 1 - The total operating income for 2025 reached 80113.56 million yuan [2] - The year-on-year growth rate of 122.60% indicates a strong performance compared to the previous year [2]

Group 1 - The core announcement is that Dize Pharmaceutical has changed its continuous supervision sponsor representative from Xu Chao to Mr. Blueprint, who will work alongside Ding Mingming for the company's IPO and 2023 annual private placement supervision, effective until December 31, 2027 [2]

Core Viewpoint - Dizh Pharmaceutical (688192) reported a significant increase in revenue for the fiscal year 2025, achieving approximately 800 million yuan, which represents a year-on-year growth of 122.6% while also reducing net losses to 763 million yuan [1] Group 1: Financial Performance - The company achieved a revenue of about 800 million yuan, marking a year-on-year increase of 122.6% [1] - The net profit attributable to shareholders was reported at -763 million yuan, indicating a reduction in losses compared to the previous year [1] Group 2: R&D and Product Development - Continuous investment in research and development is identified as a key factor for the company's high-quality growth [1] - The reporting period marks the first accounting year for two of the company's products included in the national medical insurance, leading to rapid sales growth [1] - Sales revenue from these products reached a total of 800 million yuan, with product launches expected to significantly impact the company's financial performance [1]

Core Viewpoint - The company reported significant revenue growth for 2025, with total revenue reaching 801 million yuan, a year-on-year increase of 122.6%, while the net loss decreased to 763 million yuan from 846 million yuan in the previous year [1] Financial Performance - Total revenue for 2025 was 801 million yuan, reflecting a 122.6% increase compared to the previous year [1] - The net loss attributable to the parent company was 763 million yuan, an improvement from a loss of 846 million yuan in the prior year [1] Product Development and Market Impact - Two products,舒沃哲® (generic name:舒沃替尼片) and高瑞哲® (generic name:戈利昔替尼胶囊), were included in the national medical insurance drug list for the first time, enhancing patient accessibility [1] - The company has intensified product promotion efforts and is actively expanding market share, positively impacting its operations [1]

Core Viewpoint - DIZHE Pharmaceutical (688192.SH) reported a significant financial performance for the fiscal year 2025, with total revenue of 800 million yuan, but also recorded substantial losses in operating profit and net profit [1] Financial Performance - The company achieved total operating revenue of 800 million yuan for the year 2025 [1] - Operating profit was reported at -766 million yuan, indicating a loss [1] - The net profit attributable to the parent company was -763 million yuan [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -842 million yuan [1] Product Development and Market Impact - Continuous investment in research and development is crucial for the company's high-quality growth, particularly in the field of innovative drugs [1] - The reporting period marks the first accounting year for two of the company's products included in the national medical insurance, leading to rapid sales growth [1] - The combined sales revenue from these products reached 800 million yuan, highlighting the impact of product launches on the company's financial status [1]

证券代码：688192 证券简称：迪哲医药 公告编号：2026-010 迪哲（江苏）医药股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迪哲（江苏）医药股份有限公司（以下简称"公司"）于近日收到持续督导 保荐机构华泰联合证券有限责任公司（以下简称"华泰联合"）出具的《关于更 换迪哲（江苏）医药股份有限公司首次公开发行股票及 2023 年度向特定对象发 行 A 股股票持续督导保荐代表人的函》。 公司首次公开发行股票并于 2021 年 12 月 10 日在上海证券交易所科创板上 市，聘请了中信证券股份有限公司（以下简称"中信证券"）担任首次公开发行 股票并在科创板上市的保荐机构，中信证券指派丁元女士、彭浏用先生担任保荐 代表人，持续督导期至 2024 年 12 月 31 日止。 公司于 2023 年 3 月 24 日召开第一届董事会第十六次会议、于 2023 年 4 月 14 日召开 2022 年年度股东大会，审议通过了《2023 年度向特定对象发行 A 股 股票预案》等相关议案。 ...

Financial Performance - The company achieved total operating revenue of 801.14 million yuan in 2025, representing a 122.60% increase compared to the previous year[3] - The net loss attributable to the parent company was 763.31 million yuan, a reduction of 82.65 million yuan from the previous year's loss[7] - The company's total assets increased by 74.69% to 3.00 billion yuan, while equity attributable to the parent company surged by 568.16% to 1.29 billion yuan[3] - The weighted average return on net assets improved to -73.92%, up from -161.12% in the previous year, indicating a positive trend in financial performance[3] Research and Development - Research and development expenses for the year amounted to 855.61 million yuan, reflecting the company's commitment to innovation[8] - The company is actively expanding the application potential of its commercialized products, with ongoing clinical trials for Shuwozhe® and Gaoruizhe® in NSCLC[12] Product Development and Approval - The company successfully launched two products, Shuwozhe® and Gaoruizhe®, which were included in the national medical insurance directory, significantly enhancing patient accessibility[6] - Shuwozhe® received FDA approval for treating adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, marking a significant milestone in the company's product portfolio[9] - The company’s subsidiary obtained a drug production license, ensuring qualifications for future commercial production[12] Capital and Liquidity - The company raised 1.773 billion yuan through a private placement of shares, significantly boosting its liquidity and capital reserves[7]

Core Viewpoint - Dize Pharmaceutical reported a significant increase in revenue for 2025, with a total of 801 million yuan, representing a year-on-year growth of 122.60% [1] Financial Performance - The company achieved a revenue of 801 million yuan in 2025, which is a 122.60% increase compared to the previous year [1] - The net profit attributable to the parent company was -763 million yuan, an improvement from -846 million yuan in the same period last year [1] Product Development and Market Expansion - Two products, Shuwozhe® (generic name: Shuwotini tablets) and Gaoruizhe® (generic name: Golexini capsules), have been included in the national medical insurance drug list, enhancing patient accessibility [1] - The company is actively promoting its products and expanding market share, which has positively impacted its operations [1]